Lantern Pharma is proud to be featured by a multitude of media outlets. Our goal is to crush cancer, and by spreading word of our innovative technology we hope to open the door to more collaborations and partnerships than ever, to empower us to develop the right treatments for the right patients.
MonMay 3rd, 2021
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform
Lantern Pharma and Actuate Therapeutics Announce Research & Development [...]
ThuApr 29th, 2021
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company’s Strategy to Develop the World’s Largest A.I. Platform for Oncology-Focused Drug Development & Rescue
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug [...]
TueApr 13th, 2021
New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations
By: Aditya Kulkarni, Joseph Ryan McDermott, Umesh Kathad, Rama Modali, [...]
ThuMar 4th, 2021
A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications
By Umesh Kathad, Aditya Kulkarni, Joseph Ryan McDermott, Jordan Wegner, [...]
MonJan 25th, 2021
Technology Is Rapidly Changing Cancer Care
By Sai Balasubramanian, J.D., Forbes
ThuDec 10th, 2020
AI offers promise but faces barriers in drug development
By Joel Berg, MedCityNews